isobutyrylshikonin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isobutyrylshikonin: from root of Lithospermum erythrorhizon; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Lithospermum	genus	A plant genus of the family BORAGINACEAE. Members contain lithospermans and lithospermic acid.[MeSH]	Boraginaceae	The Borage plant family is in the class Magnoliopsida, subclass Asteridae, order Lamiales. It is characterized by hairy foliage, usually alternate and simple; flowers are funnel-shaped or tubular. Some of the species contain PYRROLIZIDINE ALKALOIDS.[MeSH]

Cross-References

ID Source	ID
PubMed CID	479500
SCHEMBL ID	3298557
MeSH ID	M000608176

Synonyms (12)

Synonym
[(1r)-1-(5,8-dihydroxy-1,4-dioxonaphthalen-2-yl)-4-methylpent-3-enyl] 2-methylpropanoate
isobutylshikonin
C17414
isobutyrylshikonin
SCHEMBL3298557
52438-12-7
AC-35024
FT-0770577
Q27155026
MS-25632
DTXSID901316067
CCA43812

Research Excerpts

Compound-Compound Interactions

Excerpt	Reference	Relevance
" In this study, we investigated erlotinib in combination with shikonin and 14 shikonin derivatives in parental U87MG and transfected U87MG."	( Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib. Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q, 2015)	0.42

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
hydroxy-1,4-naphthoquinone	Any member of the class of 1,4-naphthoquinones in which the naphthoquinone moiety is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.72 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.51 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.11	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
pyrrolidine dithiocarbamate pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine.	2.1	1	dithiocarbamic acids; pyrrolidines	anticonvulsant; antineoplastic agent; geroprotector; neuroprotective agent; NF-kappaB inhibitor; radical scavenger
deoxyshikonin deoxyshikonin: isolated from Lithospermum erythrorhizon	2.11	1	hydroxy-1,4-naphthoquinone
erlotinib hydrochloride [no description available]	2.11	1	hydrochloride; terminal acetylenic compound	antineoplastic agent; protein kinase inhibitor
acetylshikonin acetylshikonin: from roots of Boraginacea; RN given refers to cpd without isomeric designation	2.54	2
shikonin shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities	7.57	2	hydroxy-1,4-naphthoquinone
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	3.25	5
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.1	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic

Condition	Relationship Strength	Studies
Cancer of Mouth [description not available]	2.25	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.25	1
Central Nervous System Disease [description not available]	2.1	1
Innate Inflammatory Response [description not available]	2.1	1
Central Nervous System Diseases Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.	2.1	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.1	1
Astrocytoma, Grade IV [description not available]	2.11	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.11	1

chemdatabank.com